lapatinib ditosylate CAS No.388082-77-7 Pharmaceutical Intermediates

Introducing Lapatinib Dimesylate, a highly effective pharmaceutical compound designed for targeted cancer therapy. Our products are the first choice for oncology applications due to their superior purity, stability and efficacy. As a factory integrating production and trading, we take pride in providing high-quality products at competitive prices, backed by our expertise and commitment to customer satisfaction.

product details

Product details

Product detail

Lapatinib dimesylate is a potent dual tyrosine kinase inhibitor that specifically targets the epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2). The compound is primarily used to treat breast cancer, particularly in patients with HER2-positive tumors. By inhibiting these key pathways, lapatinib dimesylate plays a vital role in slowing tumor growth and improving patient outcomes.

product detail

CAS No.	40856-44-8
EINECS	609-874-3
Formula	C9H11NO2
Molecular Weight	165.19
Appearance	White to Off-White solid
Purity	≥98%
Type	Pharmaceutical Intermediates

Physical and Chemical Properties

Lapatinib dimesylate possesses several key physical and chemical properties that contribute to its effectiveness in pharmaceutical applications:

- Molecular formula: C36H34ClFN4O7S2

- Molecular weight: 753.26 g/mol

- Appearance: The compound is usually a Light yellow powder, indicating high purity and quality.

- Solubility: Lapatinib ditosylate is soluble in organic solvents such as dimethyl sulfoxide (DMSO) and methanol, facilitating its incorporation into various formulations.

- Stability: The compound exhibits excellent thermal and chemical stability, ensuring its reliability during storage and use.

These properties make lapatinib dimesylate a valuable asset to the pharmaceutical industry, where precision and consistency are critical for effective cancer treatment.

Advantages

1. Targeted Therapy: Lapatinib dimesylate specifically targets HER2-positive cancer cells, providing a more effective treatment option for patients with this type of breast cancer.

2. High Purity: Our manufacturing process ensures that lapatinib dimesylate contains very low levels of impurities, which is critical for pharmaceutical applications where quality control is critical.

3. Enhanced efficacy: Dual inhibition of EGFR and HER2 pathways can improve treatment outcomes, making lapatinib dimesylate the first choice for oncologists.

4. Cost Effective: By integrating production and trading, we are able to offer competitive prices without compromising quality, providing our customers with excellent value for investment.

5. Expert Support: Our experienced team of professionals is committed to providing excellent customer service and technical support, ensuring our customers have the resources they need to succeed.

Application

Lapatinib dimesylate is widely used in the pharmaceutical industry for a variety of applications, including:

- Cancer Treatment: The primary application of lapatinib dimesylate is the treatment of HER2-positive breast cancer, where it has been shown to improve patients’ progression-free survival.

- Combination Therapy: Lapatinib dimesylate is often used in combination with other therapies, such as chemotherapy or hormone therapy, to enhance the overall treatment effect and patient outcomes.

- Research: Researchers used lapatinib dimesylate in laboratory studies to explore new approaches and mechanisms of action for cancer treatment.

In summary

In conclusion, Lapatinib Dimesylate is a high-quality pharmaceutical compound that offers many advantages for targeted cancer therapy. With its superior purity, stability, and efficacy, it is an important component in the fight against HER2-positive breast cancer. As a factory integrating production and trading, we are committed to providing our customers with the best products and services on the market. Choose Lapatinib Dimesylate to meet your pharmaceutical needs and experience the difference in quality and performance.